VolitionRx (VNRX) Insider Trading & Ownership $0.84 +0.03 (+3.70%) (As of 01:01 PM ET) Add Compare Share Share Insider Trades Stock AnalysisChartEarningsHeadlinesInsider TradesShort Interest VolitionRx (NYSEAMERICAN:VNRX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage15.40%Number OfInsiders Buying(Last 3 Years)6Amount OfInsider Buying(Last 3 Years)$801,506.94Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$64,424.03 Get VNRX Insider Trade Alerts Want to know when executives and insiders are buying or selling VolitionRx stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VNRX Insider Buying and Selling by Quarter Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. VolitionRx Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/16/2023Cameron John ReynoldsCEOBuy10,000$1.22$12,200.00 6/2/2023Salvatore Thomas ButeraCEOBuy10,000$1.59$15,900.00 2/22/2023Guy Archibald InnesDirectorBuy234,000$1.75$409,500.00 12/19/2022Jacob Vincent MicallefInsiderBuy25,000$2.30$57,500.00 12/19/2022Salvatore Thomas ButeraCEOBuy5,000$2.27$11,350.00 12/16/2022Jacob Vincent MicallefInsiderBuy7,339$1.96$14,384.44 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/16/2022Martin Charles FaulkesDirectorBuy55,000$2.10$115,500.00 12/12/2022Salvatore Thomas ButeraCEOBuy4,350$2.09$9,091.50 12/8/2022Nicholas PlummerInsiderBuy4,800$2.07$9,936.00 11/28/2022Salvatore Thomas ButeraCEOBuy5,000$2.21$11,050.00 9/19/2022Jacob Vincent MicallefInsiderBuy13,000$1.70$22,100.00 8/30/2022Cameron John ReynoldsCEOBuy3,500$1.61$5,635.00 8/26/2022Jacob Vincent MicallefInsiderBuy29,000$1.74$50,460.00 8/22/2022Salvatore Thomas ButeraCEOBuy5,000$1.64$8,200.00 8/2/2022Guy Archibald InnesDirectorBuy12,500$2.00$25,000.00 6/6/2022Jason Bradley Md TerrellInsiderSell14,949$2.47$36,924.03 5/16/2022Guy Archibald InnesDirectorBuy10,000$2.37$23,700.00 4/11/2022Jason Bradley Md TerrellInsiderSell10,000$2.75$27,500.00 (Data available from 1/1/2013 forward) VNRX Insider Trading Activity - Frequently Asked Questions Who is on VolitionRx's Insider Roster? The list of insiders at VolitionRx includes Cameron John Reynolds, Guy Archibald Innes, Jacob Vincent Micallef, Jason Bradley Md Terrell, Martin Charles Faulkes, Nicholas Plummer, and Salvatore Thomas Butera. Learn more on insiders at VNRX. What percentage of VolitionRx stock is owned by insiders? 15.40% of VolitionRx stock is owned by insiders. Learn more on VNRX's insider holdings. Which VolitionRx insiders have been buying company stock? The following insiders have purchased VNRX shares in the last 24 months: Cameron John Reynolds ($12,200.00), Guy Archibald Innes ($409,500.00), Jacob Vincent Micallef ($71,884.44), Martin Charles Faulkes ($115,500.00), Nicholas Plummer ($9,936.00), and Salvatore Thomas Butera ($47,391.50). How much insider buying is happening at VolitionRx? Insiders have purchased a total of 360,489 VNRX shares in the last 24 months for a total of $666,411.94 bought. VolitionRx Key ExecutivesDr. Martin Charles Faulkes Ph.D. (Age 80)Executive Chairman Compensation: $239.51kMr. Cameron Reynolds MBA (Age 53)Founder, CEO, President & Director Compensation: $572.43kDr. Gaetan Michel Ph.D. (Age 50)Chief Operating Officer Compensation: $518.15kDr. Salvatore Thomas Butera DVM (Age 72)Chief Executive Officer of Volition Veterinary Diagnostics Development LLC Compensation: $477.25kMr. Terig Hughes (Age 53)CFO & Treasurer Compensation: $338.74kDr. Jacob Vincent Micallef MBA (Age 68)Ph.D., Chief Scientific Officer Compensation: $571.55kMr. Nicholas Plummer (Age 53)Group General Counsel Ms. Louise Batchelor Day (Age 52)Group Chief Marketing & Communications Officer Mr. Thomas BygottSales & Marketing DirectorMr. Gael Forterre M.B.A. (Age 42)Chief Commercial Officer More Insider Trading Tools from MarketBeat Related Companies TScan Therapeutics Insider Selling Solid Biosciences Insider Selling Lexeo Therapeutics Insider Selling MacroGenics Insider Selling Amarin Insider Selling Corbus Pharmaceuticals Insider Selling Inhibrx Insider Selling Acrivon Therapeutics Insider Selling Enanta Pharmaceuticals Insider Selling Editas Medicine Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NYSEAMERICAN:VNRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
